News
Anebulo Pharmaceuticals
ANEB · OTC
$0.295+$0.2943 (+42042.86%)TodayMarket closed ·
No price history for this range.
Latest news
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates
- News
12 Health Care Stocks Moving In Friday's Intraday Session
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces Final Results of Tender Offer
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- NewsAvi Kapoor
Crude Oil Jumps 2%; Chicago Fed National Activity Index Improves Slightly In September
- NewsAvi Kapoor
US Stocks Higher; Nasdaq Surges Over 100 Points
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity
- NewsAnthony Noto
Deal Dispatch: Need M&A Approval? FCC Chair Explains How To Get It
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces Update on Going Private Transaction and Strategic Alternatives
- NewsAvi Kapoor
Crude Oil Falls; Thermo Fisher Scientific Earnings Top Views
- NewsAvi Kapoor
Dow Surges Over 200 Points; AT&T Posts Upbeat Earnings
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates
- News
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- News
Anebulo Pharmaceuticals Announces FDA Feedback For IV Selonabant To Address Cannabis-Induced Toxicity In Children And Completes $15M Capital Raise; Phase I Study Planned For 1H25
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2025 Financial Results and Recent Updates
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates
- Press releaseBusiness Wire
Anebulo Pharmaceuticals Awarded NIDA Grant for its Investigational IV Treatment for Acute Cannabis-Induced Toxic Effects
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.